In surprise move, RFK Jr.'s vaccine committee votes to recommend RSV shot for infants
In their first vote since appointed by Health and Human Services Secretary Robert F. Kennedy, the eight members of a vaccine committee voted to recommend a shot that protects infants against respiratory syncytial virus, or RSV.
Clesrovimab, a monoclonal antibody created by pharmaceutical giant Merck, is recommended for use in infants younger than eight months born during or entering their first RSV season.
Martin Kulldorff, who led the June 26 meeting, recently served as an expert witness for plaintiffs who accused Merck of concealing the risks of Gardasil, a vaccine used to prevent cancer from human papillomavirus, or HPV.
The eight new ACIP members met for the first time on June 25. Kennedy fired all 17 original members of the committee on June 9 and appointed its new members a few days later. Given the inclusion of vaccine skeptics, the approval comes as a surprise to close watchers of the panel.
Experts from the Centers for Disease Control and Prevention's workgroup that presented data on the drug universally supported the drug. However, two panel members still voted against it.
RSV infects nearly everyone by the time they're 2. It causes cold symptoms, affecting the breathing passages and lungs, according to the CDC. In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year, and several hundred die.
ACIP's first meeting: Inside the unusual, RFK-appointed panel that's deciding on childhood vaccines
Merck's shot is the second RSV monoclonal antibody on the market. The first, a shot from Sanofi and AstraZeneca called Beyfortus, was approved by the Food and Drug Administration in July 2023 and prevents RSV lower respiratory tract disease in infants entering or during their first RSV season.
It was the first of its kind to be widely available to everyone beyond a small population of immunocompromised children. Data presented during the June 25 ACIP meeting found the shot reduced hospitalizations by about 47% in newborns up to two months old, the population at highest risk of hospitalization.
Dr. Cody Meissner, who voted to recommend the Merck shot, said on June 25 that the result data from Beyfortus in the last RSV season was an 'astonishing accomplishment.'
Beyfortus shot that was recommended by ACIP in 2023 for babies under 9 months old who are entering their first RSV season. It's also recommended for babies 8 to 19 months who are at increased risk of severe disease if they're entering their second season of RSV.
Parents will have the choice between the two shots. If they receive Beyfortus, they're not recommended to get the new monoclonal antibody by Merck.
Pregnant patients also have access to Pfizer's RSV vaccine Abrysvo, which is recommended for pregnant people to protect newborns from lower respiratory infections. The shot is approved for use during the 32nd and 26th weeks of pregnancy during the RSV season, which typically starts in September and runs through January in the U.S.
Adrianna can be reached at adrodriguez@usatoday.com.
This article originally appeared on USA TODAY: RFK Jr.'s new ACIP votes to recommend RSV shot for infants
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
5 hours ago
- Wall Street Journal
RFK Jr.'s Vaccine Panel Has a New Approach: Question Everything
ATLANTA—Retsef Levi wasn't convinced. Data for a new drug showed it can help keep babies out of the hospital with respiratory syncytial virus, or RSV. Scientists of the Centers for Disease Control and Prevention presented the evidence in a long series of slides to the federal vaccine panel recently remade by Health and Human Services Secretary Robert F. Kennedy Jr. Outside experts considered recommending the drug an obvious choice for the Levi, a new member of the panel and a Massachusetts Institute of Technology operations-management professor, said he thinks about other things when considering immunizations, including his experience as a father of six. He was one of two members to vote 'no' on a recommendation for the drug, which the five other members passed.
7 hours ago
Kennedy's vaccine committee to vote on flu vaccines and controversial preservative
ATLANTA -- U.S. Health Secretary Robert F. Kennedy Jr.'s new vaccine advisory committee backed another option to protect infants against a dangerous virus — before turning to questions about fall flu vaccines and a preservative in a small fraction of them that some antivaccine groups have falsely tied to autism. The Advisory Committee on Immunization Practices on Thursday took up protections against RSV, or respiratory syncytial virus, a common cause of cold-like symptoms that can dangerously inflame infants' tiny airways. In 2023, U.S. health officials began recommending two new measures to protect infants — a lab-made antibody for newborns and a vaccine for pregnant women — that experts say likely drove an improvement in infant mortality. That first antibody, called nirsevimab, proved to be 63% to 76% effective against emergency department visits for infants over the last year. On Thursday, the vaccine panel voted 5-2 that another newly approved antibody shot, Merck's clesrovimab, should be used similarly. The ACIP, created more than 60 years ago, helps the Centers for Disease Control and Prevention determine who should be vaccinated against a long list of diseases, and when. Those recommendations have a big impact on whether insurance covers vaccinations and where they're available. Kennedy was a leading voice in the antivaccine movement before becoming the nation's top health official. He fired the previous 17-member panel this month and replaced it with a seven-member group that includes several vaccine skeptics. At its June meetings, the committee usually refreshes guidance for Americans 6 months and older to get a flu shot, and helps propel the annual fall vaccination campaign. Presentations prepared for Thursday's meeting suggest that the panel may do much the same this year. But there's also a flu-related vote that promises controversy. It concerns thimerosal, a form of mercury that's been added to vaccines since the early 20th century to preventing bacterial contamination in multi-dose vials. Kennedy has long held there was a tie between thimerosal and autism, and also accused the government of hiding the danger. Study after study has found no evidence that thimerosal causes autism. But since 2001, vaccines manufactured for the U.S. market and routinely recommended for children 6 years or younger have contained no thimerosal or only trace amounts, with limited exceptions. Thimerosal was placed on the meeting agenda shortly after Kennedy's new vaccine advisory was named last week. Before the vote, the committee will hear from Lyn Redwood, the former president of what is now known as Children's Health Defense — an antivaccine group founded by Kennedy. Some public health experts contend the thimerosal discussion will unnecessarily raise doubt in vaccines while possibly also making them more expensive and harder to get this fall. At the panel's meeting Wednesday, Chrissie Juliano, executive director of the Big Cities Health Coalition, lamented the ouster of the former ACIP panel and the agenda of the new one. Her organization, which represents large city health departments, 'is deeply concerned that many routine vaccines may soon become inaccessible or unaffordable for millions of Americans if ACIP makes changes based on ideology rather than science," she said. "The stakes are simply too high to let that happen.' ___ Neergaard reported from Washington. ___
Yahoo
8 hours ago
- Yahoo
Anti-vaccine activist presents data to RFK Jr.'s reshaped CDC advisory panel
A longtime anti-vaccine activist gave a presentation at the Centers for Disease Control and Prevention's vaccine advisory committee meeting Thursday on an issue that has long been considered settled science. It was perhaps the clearest sign of how meetings of the panel, called the Advisory Committee on Immunization Practices, have already changed drastically under Health and Human Services Secretary Robert F. Kennedy Jr., who recently fired all 17 members of the panel and replaced them with a group of his own appointees. The presenter, nurse practitioner Lyn Redwood, is the president emerita of Children's Health Defense, the anti-vaccine group founded by Kennedy. Her presentation focused on thimerosal, a mercury-based preservative that had previously been used in some vaccines. Since 2001, however, nearly all vaccines made in the United States contain no thimerosal or only trace amounts. The exception is the multi-dose flu shot vials, though most flu shots now come in single-dose packaging that doesn't contain the preservative. Anti-vaccine activists have long claimed that thimerosal is linked to autism, but the link has been widely debunked. Redwood referenced 'neurodevelopmental disorders' rather than autism in her presentation, but after the presentation asserted links between thimerosal and brain inflammation, which she called 'one of the hallmarks that we see in autism.' A background briefing document that was available on the CDC's website Tuesday said that a summary of studies found 'no association between prenatal exposure to thimerosal-containing vaccinations and autism spectrum disorder in children.' The document was taken down Wednesday without explanation. ACIP member Dr. Robert Malone said Thursday during the meeting that, based on his understanding, 'that article was not authorized by the Office of the Secretary and has been removed.' Dr. David Higgins, a pediatrician and preventive medicine specialist at the University of Colorado Anschutz Medical Campus, decried the document's removal. 'Decades of evidence were ignored or even hidden,' said Higgins, who wasn't a part of the meeting. 'That's not being transparent. That's not scientific integrity.' Following the presentation, the committee voted 5-1 to recommend that children, adults and pregnant women get single-dose thimerosal-free flu vaccines. One member, Vicky Pebsworth, abstained. Before ACIP recommendations are implemented, the CDC director must sign off on them. However, there is currently no director in place as the nominee for the position, Susan Monarez, awaits confirmation by the Senate. In the absence of a director, Kennedy has the authority to adopt the ACIP's recommendations. ACIP recommendations do not mean the multi-dose vials are banned; for that to happen the Food and Drug Administration would need to revoke approval. Thimerosal-free flu shots account for the majority of the doses given in the U.S. Just 4%-5% of flu vaccines used during the 2024-2025 season were multi-dose, thimerosal-containing vaccines, Tracey Beth Høeg, a special advisor to the FDA commissioner, said during the meeting. Dr. Cody Meissner, a pediatrician, was the lone dissenting vote. 'The risk from influenza is so much greater than the nonexistent, as far as we know, risk from thimerosal,' Meissner said of his vote. 'I would hate for a person not to receive the influenza vaccine because the only available preparation contains thimerosal. I find that very hard to justify.' Meissner had initially followed up Redwood's presentation by saying he wasn't sure how to respond to it. 'This is an old issue that has been addressed in the past,' he said. Multiple infectious disease experts said on a Thursday press call following the ACIP meeting that multi-dose vaccines can be useful for vaccinating large groups such as workers. The decision not to recommend thimerosal-containing vaccines could also dissuade other countries — where multi-dose vials are more common — from using them, thereby reducing vaccine access, they added. Dr. Sean O'Leary, the American Academy of Pediatrics' liaison to ACIP, called Redwood's presentation 'unprecedented.' 'That was a highly-biased presentation full of cherry-picked data and junk science,' O'Leary said. 'The vast majority of it wasn't actually relevant to thimerosal in vaccines.' O'Leary told reporters in a call on Thursday that the AAP chose not to participate in the meeting, which it usually does. 'This meeting showcased an ACIP that has drifted so far from its long-standing focus on science, evidence and public health. When that focus returns, we will, too,' he said. Higgins, the Colorado pediatrician who was not part of the meeting, said, 'it's outrageous that a decision as consequential as this would be decided based on a single presentation from someone who arguably is not an expert in the field.' Redwood's presentation also triggered a slew of responses from representatives of major medical organizations participating in the meeting, who questioned the veracity of the data presented and asked to see credible scientific evidence. 'Will there be an actual CDC presentation done by staff scientists, physicians and those who are subject matter experts with accurate, peer-reviewed scientific data,' Dr. Jason Goldman, American College of Physicians' liaison to ACIP, asked the committee, 'or will we have lay person presentations only?' Committee Chair Martin Kulldorff, a biostatistician who has criticized pandemic lockdowns and Covid vaccines, scolded those representatives for their pushback. 'I think it's inappropriate to dismiss a presentation just because the person does not have a Ph.D., or an MD,' he said. 'There are a lot of knowledgeable people who we would like to hear from, and we want to hear from a variety of viewpoints. And I think today's discussion is a very good example that we have received input from a variety of people on this topic.' In a separate vote, the committee reaffirmed the existing recommendation that people ages 6 months and older should get annual flu shots, with six votes in favor. Pebsworth again chose to abstain. Earlier Thursday, the committee voted on whether to recommend an RSV drug for infants younger than 8 months. Five members voted in favor and two voted against, providing the majority vote needed for the recommendation to pass. The drug up for a vote Thursday, clesrovimab, is a monoclonal antibody injection that can prevent lower respiratory disease in infants during or before their first RSV season, which typically starts in the fall and peaks in the winter. RSV leads to up to 300 deaths a year among those younger than 5 in the U.S. A dramatic spike in severe RSV overwhelmed children's hospitals in late 2022. Clesrovimab was approved by the Food and Drug Administration earlier this month. A similar drug, nirsevimab, has also been approved for infants and some young children since 2023. A vaccine for pregnant women that also protects newborns is approved as well. Meissner, who was part of the committee's work group on RSV, fielded questions from fellow members about the trial data and the disease itself. He explained how newborns' tiny airways put them at higher risk for severe illness. That risk, he said, falls in their second year of life, when the airways are larger. The work group determined that the drug was effective at preventing severe RSV in young infants and had a favorable safety profile. 'These are truly remarkable products. They are safe and they're effective,' Meissner said. 'The FDA has spent an enormous amount of time looking at safety and efficacy.' Despite this, two members of the group, Retsef Levi and Vicky Pebsworth, questioned the drug's safety and voted not to recommend it. This article was originally published on
